5000



# STIC Biotechnology Systems Branch

## RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:  $\frac{10/522,827}{907/0}$ Date Processed by STIC:  $\frac{2/15/05}{2}$ 

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 4.2.2 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- 3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
  U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

# Raw Sequence Listing Error Summary

	10/572.8	99	1/
RROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 10/522, 8		•
	s: Please disregard english "alpha" headers, which were inser		
1Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This r was retrieved in a word processor after creating it. Please adjust your right mar prevent "wrapping."	nay occur if yo gin to .3; this w	ur file vill
2Invalid Line Length	h The rules require that a line not exceed 72 characters in length. This includes w		
3Misaligned Amino Numbering	use space characters, instead.		
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequensure your subsequent submission is saved in ASCII text.	ence Rules. Pl	ease
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per each n or Xaa can only represent a single residue. Please present the maxim residue having variable length and indicate in the <220>-<223> section that some	ium number of	eacn
6PatentIn 2.0 "bug"	A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be miss sequences(s) Normally, Patentin would automatically generate previously coded nucleic acid sequence. Please manually copy the relevant <2 the subsequent amino acid sequence. This applies to the mandatory <220>-< Artificial or Unknown sequences.	20>-<223> section from	tion to
7Skipped Sequences (OLD RULES)	es Sequence(s) missing. If intentional, please insert the following lines for (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is sh (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheading: (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "This sequence is intentionally skipped	own) s under this hea	
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include	the skipped se	quences.
8Skipped Sequences (NEW RULES)	ses Sequence(s) missing. If intentional, please insert the following lines <210> sequence id number <400> sequence id number 000	or each skippe	d sequence.
9Use of n's or Xaa's (NEW RULES)	Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if it is of In <220> to <223> section, please explain location of n or Xaa, and which res	Siduc II OI Xaa	represents.
Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, scientific name (Genus/species). <220>-<223> section is required when <21 is Artificial Sequence	3/ Tesponse is	Olikilowii o
11Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric in Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Unknown." Please explain source of genetic material in <220> to <223> sec (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec.	Artificial Sequention.  1.823 of Sequenti	ence Rules)
PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This caus resulting in missing mandatory numeric identifiers and responses (as indicate listing). Instead, please use "File Manager" or any other manual means to co	py file to floppy	1100
13 Misuse of n/Xaa	"n" can only represent a single <u>nucleotide;</u> "Xaa" can only represent a single	amino acid	
-	AMC - Biotechnology Systems Branch - 09/09/2003		



Does Not Comply

Corrected Diskette Needer

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/522,827

DATE: 02/11/2005 TIME: 16:12:58

Input Set : A:\PTO.YF.txt

Output Set: N:\CRF4\02112005\J522827.raw

```
5 <110> APPLICANT: Lek Pharmaceuticals d. d.
W--> 6 <120> TITLE OF INVENTION: Synthetic gene coding for human granulocyte-colony
```

stimulating factor for the expression in E. coli

C--> 8 <140> CURRENT APPLICATION NUMBER: US/10/522,827 w--> 7

C--> 8 <141> CURRENT FILING DATE: 2005-01-31

W--> 0 <130> FILE REFERENCE:

W--> 8 <160> NUMBER OF SEQ ID: 2

# see p. L

### ERRORED SEQUENCES

E--> 11 <210> SEQ ID NO: SEQ ID NO: 1

12 <211> LENGTH: 525 base pairs

13 <212> TYPE: DNA

14 <213> ORGANISM: synthetic sequence

W--> 15 <220> FEATURE: gene

W--> 16 <400> SEQUENCE: SEQ ID NO: 1

E--> 18 atgacaccac tgggtccagc ttcttctctg ccgcaaagct ttctgttgaa atgtttagaa E--> 19 caagttegta aaatteaagg tgatggtgca getttacaag aaaaactgtg tgcaacttat E--> 20 aaactgtgtc atccagaaga actggttctg ttaggtcatt ctctgggtat tccgtgggct

E--> 21 cctctgagct cctgtccgag ccaggcgctg cagctggcag gctgcctgag ccaactgcat E--> 22 ageggtetgt ttetgtatea gggtetgetg caggegetgg aaggeattte eceggaactg

E--> 23 gggcccacct tggacacact gcagctggac gtcgccgact ttgccaccac catctggcag E--> 24 cagatggaag aactgggaat ggcccctgcc ctgcagccca cccagggtgc catgccggcc

E--> 25 ttcgcctctg ctttccagcg ccgtgcaggt ggggtcctgg ttgctagcca tctgcaatct

E--> 26 tttctggaag ttagctatcg tgttctgcgt catctggctc agccg

E--> 28 <210> SEQ ID NO: SEQ ID NO: 2

29 <211> LENGTH: 528 base pairs

30 <212> TYPE: DNA

31 <213> ORGANISM: synthetic sequence

W--> 32 <220> FEATURE: gene

W--> 33 <400> SEQUENCE: SEQ ID NO: 2

E--> 34 atgacaccac tgggtccagc ttcttctctg ccgcaaagct ttctgttgaa atgtttagaa E--> 35 caagttegta aaatteaagg tgatggtgca getttacaag aaaaactgtg tgcaacttat E--> 36 aaactgtgtc atccagaaga actggttctg ttaggtcatt ctctgggtat tccgtgggct E--> 37 cetetgaget cetgteegag ceaggegetg cagetggeag getgeetgag ceaactgeat

E--> 38 ageggtetgt ttetgtatea gggtetgetg caggegetgg aaggeattte eeeggaactg E--> 39 gggcccacct tggacacact gcagctggac gtcgccgact ttgccaccac catctggcag

E--> 40 cagatggaag aactgggaat ggcccctgcc ctgcagccca cccagggtgc catgccggcc E--> 41 ttcgcctctg ctttccagcg ccgtgcaggt ggggtcctgg ttgctagcca tctgcaatct

E--> 42 tttctggaag ttagctatcg tgttctgcgt catctggctc agccgtga

2/11/0

### SEQUENCE LISTING


		<i>1</i> )
	.110.	Lek Pharmaceuticals d. d.
	<110>	Her indimacederate a. a.
	<120>	Synthetic gene coding for human granulocyte-colony
1		factor for the expression in E. coli
	<160>	2 1 Not wit almospherical (1417) identifiers
		114 - do NoTingert alphabetical
		delete-do NoT insert alphabetical 2141) identifiers and
	<210>	-SEQ-ID-NO: 1
	<211>	525 base pairs / Om M
	<212>	Synthetic sequence many furnary
	<213>	(synthetic sequence)
	<220>	SEQ ID NO: 1  525 base pairs  DNA  Synthetic sequence invalid-sele item 10 on Evro  Second ID No. 1  Second ID No. 1  Second ID No. 1  Second ID No. 1
	<400>	SEQ ID NO. 1
'	atgacaccac	
	caagttcgta	aaattcaagg tgatggtgca gctttacaag aaaaactgtg tgcaacttat 120 (- )
		atccagaaga actggttctg ttaggtcatt ctctgggtat tccgtgggct
		cctgtccgag ccaggcgctg cagctggcag gctgcctgag ccaactgcat
		ttctgtatca gggtctgctg caggcgctgg aaggcatttc cccggaactg
	gggcccacct	tggacacact gcagetggac gtcgccgact ttgccaccac catctggcag  base totals
		aactgggaat ggcccctgcc ctgcagcca cccagggtgc catgccggcc
		ctttccageg ccgtgcaggt ggggtcctgg ttgctagcca tctgcaatct
	tttctggaag	ttagctatcg tgttctgcgt catctggctc agccg
		mark )
	<210>	SEQ ID NO: 2
	<211>	528 base pairs
	<212>	DNA
	<213>	Synthetic sequence
	<220>	-gene FYI; "gene" 12 / Not will for (213) Artifliand segletion
	<400>	DNA  Synthetic sequence  gene FYI; "gene" is not a sufficient synloration  SEQ ID NO. 2  tgggtccage ttettetetg cegeaaaget ttetgttgaa atgtttagaa
	caagttcgta	aaattcaagg tgatggtgca gctttacaag aaaaactgtg tgcaacttat
		atccagaaga actggttctg ttaggtcatt ctctgggtat tccgtgggct
		cctgtccgag ccaggcgctg cagctggcag gctgcctgag ccaactgcat
		ttctgtatca gggtctgctg caggcgctgg aaggcatttc cccggaactg
		tggacacact gcagctggac gtcgccgact ttgccaccac catctggcag
		aactgggaat ggcccctgcc ctgcagccca cccagggtgc catgccggcc
		ctttccagcg ccgtgcaggt ggggtcctgg ttgctagcca tctgcaatct
-	tttctggaag	ttagctatcg tgttctgcgt catctggctc agccgtga

1) Correll Sequence Review 2) Correll sample Sequence Listing, attacked

```
<110>
             Smith, John; Smithgene Inc.
             Example of a Sequence Listing
<120>
             01-00001
<130>
<140>
             PCT/EP98/00001
<141>
             1998-12-31
<150>
             US 08/999,999
             1997-10-15
<151>
<160>
<170>
             PatentIn version 2.0
<210>
             1
             389
<211>
<212>
             DNA
             Paramecium sp.
<213>
<220>
<221>
             CDS
<222>
             (279) . . . (389)
<300>
<301>
             Doe, Richard
             Isolation and Characterization of a Gene Encoding a
<302>
             Protease from Paramecium sp.
<303>
             Journal of Genes
<304>
             1
<305>
             4
             1-7
<306>
<307>
             1988-06-31
<308>
             123456
<309>
             1988-06-31
<400>
                                                                                        60
                                       ctgggcttct
                                                    caccctgcta
                                                                 atcagatctc
agctgtagtc
             attcctgtgt
                          cctcttctct
                                                    caggcaggca
                                                                                       120
agggagagtg
             tcttgaccct
                          cctctgcctt
                                       tgcagcttca
                                                                  ggcaggcagc
                                                    aggcttaggg
tgatgtggca
                                       cttttcagcc
                                                                  tgggttccgc
                                                                                       180
             attgctggca
                          gtgccacagg
                                                                                       240
                                                    ctctcgctct
                                                                 cctctcgctc
cgcggcgcgg
             cggccctct cgcgctcctc
                                       tcgcgcctct
```

Opsult this

															•	
ggaco	tgatt	ag	gtgag	cag	gagga	<b>33333</b>	cag	ttagc		atg Met 1	gtt Val	tca Ser	atg Met	ttc Phe 5	agc Ser	296
ttg Leu	tct Ser	ttc Phe	aaa Lys 10	tgg Trp	cct Pro	gga Gly	ttt Phe	tgt Cys 15	ttg Leu	ttt	gtt Val		ttg Leu 20	ttc	caa Gln	344
tgt Cys	ccc Pro	aaa Lys 25	gtc Val	ctc Leu	ccc Pro	tgt Cys	cac His 30	tca Ser	tca Ser	ctg Leu	cag Gln	ccg Pro 35	aat Asn	ctt Leu	•	389
<210><211><211><212><213>	•	2 37 PR Pa	T	ium s	р.			•								·
<400> Met 1		2 Ser	Met	Phe 5	Ser	Leu	Ser	Phe	Lys 10	Trp	Pro	Gly	Phe	Cys 15	Leu	
Phe	Val	Cys	Leu 20	Phe	Gln	Cys	Pro	Lys 25	Val	Leu	Pro	Cys	ніs 30	Ser	Ser	
Leu	Gln	Pro 35	Asn	Leu												
<210><211><211><212><213>	• •	3 11 PR Ar	Т	ial S	eguen	ce										
<220> <223>		De li	signe nker	d pep betwe	tide l en th	based e alph	on si	ize ar d beta	nd pol n chai	arity ns of	to a Prot	ct as ein X	a YZ .	,		
<400> Met 1		3 Asn	Leu	Glu 5	Pro	Met	His	Thr	Glu 10	Ile						,
<210> <400> 000		4														
													ŧ			



Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	М
<120>	Title of Invention	· · · · ·	М
<130>	File Reference	Personal file reference	M when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	M
<170>	Software	Name of software used to create the Sequence Listing	0
<210>	SEQ ID NO:#:	Response shall be an integer representing the SEQ ID NO shown	м -
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	М

•

М

М

<212> Type

Whether presented sequence mole-cule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the

"DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature

section.

<213> Organism

Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223>

<220> Feature

Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.

feature section.

M, under the following conditions: if "n,"
"Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGAN-ISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.

<221> Name/Key

Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6

M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence

<222> Location

Specify location within sequence; where appropriate state number of first and last bases/amino acids

M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

1/29/99 1:53 PM

	<u> </u>	in feature	base was used in a sequence
<223>	Other Information	Other relevant information; four lines maximum	M, under the fol- lowing conditions: if "n," "Xaa," or a modified or un- usual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial
	. \	•	Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<300>	Publication Information	Leave blank after <300>	0 .
<301>	Authors :	Preferably max of ten named authors of publi- cation; specify one name per line; preferable format: Surname, Other Names and/or Initials	O .
<302>	Title		O ;
<303>	Journal		0
<304>	Volume		0
<305>	Issue	·	0
<306>	Pages		0 .
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy	0
<308>	Database Accession Number	Accession number assigned by data-base including database name	0
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy	0
<310>	Patent Document Number ,	Document number; for patent-type citations only. Specify as, for example, US 07/999,999	0

<311>	Patent Filing Date	Document filing date, for patent- type citations only; specify as yyyy-mm-dd	0
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd	0
<313>	Relevant Residues	FROM (position) TO (position)	0
<400>	Sequence	SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence	. <b>M</b>

- 5. Section 1.824 is revised to read as follows:
- 1.824 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.
- (a) The computer readable form required by 1.821(e) shall meet the following specifications:
- (1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.
- (2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.
- (3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.
- (4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.
- (5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.
- (6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.
- (b) Computer readable form submissions must meet these format requirements:
- (1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;
- (2) Operating System: MS-DOS, Unix or Macintosh;